Characterization of modified mesoporous silica nanoparticles as vectors for siRNA delivery
Publication date: Available online 21 February 2018Source: Asian Journal of Pharmaceutical SciencesAuthor(s): Anna Slita, Anna Egorova, Eudald Casals, Anton Kiselev, Jessica M. RosenholmAbstractGene therapy using siRNA molecules is nowadays considered as a promising approach. For successful therapy, development of a stable and reliable vector for siRNA is crucial. Non-viral and non-organic vectors like mesoporous silica nanoparticles (MSN) are associated with lack of most viral vector drawbacks, such as toxicity, immunogenicity, but also generally a low nucleic acid carrying capacity. To overcome this hurdle, we here modified the pore walls of MSNs with surface-hyperbranching polymerized poly(ethyleneimine) (hbPEI), which provides an abundance of amino-groups for loading of a larger amount of siRNA molecules via electrostatic adsorption. After loading, the particles were covered with a second layer of pre-polymerized PEI to provide better protection of siRNA inside the pores, more effective cellular uptake and endosomal escape. To test the transfection efficiency of PEI covered siRNA/MSNs, MDA-MB 231 breast cancer cells stably expressing GFP were used. We demonstrate that PEI-coated siRNA/MSN complexes provide more effective delivery of siRNAs compared to unmodified MSNs. Thus, it can be concluded that appropriately surface-modified MSNs can be considered as prospective vectors for therapeutic siRNA delivery.Graphical abstractModified mesoporous silica nanoparticles (MSNs) wh...
Publication date: March 2019Source: European Journal of Obstetrics &Gynecology and Reproductive Biology, Volume 234Author(s): Katrin Wisslicen, Sara Brucker, Florin-Andrei Taran, Felix Neis
Publication date: March 2019Source: European Journal of Obstetrics &Gynecology and Reproductive Biology, Volume 234Author(s): Triin Tammiste, Külli Idla, Andres Salumets, Piret Veerus
Publication date: March 2019Source: European Journal of Obstetrics &Gynecology and Reproductive Biology, Volume 234Author(s): Joana Portela Dias, Mariana Coroado, António Braga, Ana Galvão, Jorge Braga
Introduction: Uterine leiomyomas are hormonally dependent benign tumors with high prevalence and morbidity. Understanding of their ethiology is so far incomplete. Several studies have confirmed that season of birth affects the incidence of some tumors: skin cancer in Italy, non-Hodgkin lymphoma and breast cancer in Sweden.
Introduction: Ovarian cancer is usually detected by peritoneal carcinomatosis with ascites.
Introduction: Cancer in reproductive age women and its treatment often results in impaired or absent reproductivity.
Introduction: Breast cancer is the top cancer and the more lethal in women worldwide. Indication for lumpectomy is breast cancer without contraindications to conservative surgery. In impalpable malignancies, wire-guided excision can be performed. Sentinel lymph node (SLN) mapping and resection is recommended for assessment of the pathologic status of the axillary lymph nodes in patients with clinical stage I and II disease. In 2016, at the authors ’ department, 134 women had surgery for breast cancer and 43.5% were submitted to lumpectomy.
Introduction: The importance of patient reported outcomes (PRO) such as “health related quality of life” (HRQoL) increases. Especially in the field of breast cancer, the most common type of cancer in women, it is very important to focus on patient's quality of life, both in adjuvant and palliative setting. Due to evolving digitalization in medicine, new possibilitie s such as electronic measurement via tablet or computer arise. However, before changing to a new mode of administration from pen and paper to an electronic, equivalence across those two different modes of administration has to be guaranteed.
Introduction: In invasive breast cancer, the detection of disseminated tumor cells (DTCs) in the bone marrow (BM) is associated with larger tumor size, axillary lymph node involvement, estrogen (ER) and progesterone (PR) receptor negativity and human epidermal growth factor receptor 2 (HER2) positivity as well as aggressive molecular subtype (non-luminal). In patients with ductal carcinoma in situ (DCIS) any such association has yet to be shown.
Introduction: Breast cancer (BC) is a heterogeneous disease caused by combination of several genetic, epigenetic and environmental factors. At about hundred single nucleotide polymorphisms significantly associate with the BC. Some of them are highly penetrant such as BRCA1 and BRCA2, but majority of them less penetrant.